The combination will now join Bristol Myers Squibb’s Opdivo in the list of bladder cancer drugs available on the NHS.

Three Motley Fool contributors think they've found unstoppable dividend stocks to buy right now. Here's why they picked ...

A new treatment regimen for advanced bladder cancer combining MSD's Keytruda with Astellas' Padcev has been given the green ...

Pfizer Inc. and Astellas Pharma Inc. have announced positive topline results from the Phase 3 EV-303 clinical trial (also ...

While this new treatment offers a vital lifeline, experts are simultaneously stressing the critical importance of recognising ...

Pfizer's oncology portfolio, boosted by Seagen and strong drug sales, fuels Q2 growth and positions the company for future ...

Friday, August 22, 2025 The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including NVIDIA Corp.

Treatment for advanced bladder cancer had not significantly changed for 40 years. Now thousands are set to benefit ...

Detailed price information for Astrazeneca Plc ADR (AZN-Q) from The Globe and Mail including charting and trades.

"Prior to the EV-302 clinical trial, the treatment of advanced bladder cancer treatment hadn't significantly changed since ...

Excitement is building as a new treatment for advanced bladder cancer that doubles survival time has been approved for NHS ...

The NHS will roll out a new treatment for advanced bladder cancer which doubles survival time. It's estimated that 1,250 ...